Valuation: Neuland Laboratories Limited

Market Cap 242B 2.54B 2.22B 2.05B 1.9B 3.61B 3.66B 24.49B 9.53B 119B 9.53B 9.32B 412B P/E 2026
42.3x
P/E 2027 * 57.7x
Enterprise Value 242B 2.54B 2.22B 2.05B 1.9B 3.6B 3.65B 24.48B 9.53B 119B 9.52B 9.31B 412B EV / Sales 2026
7.59x
EV / Sales 2027 * 10.2x
Free-Float
62.24%
Yield 2026
0.28%
Yield 2027 * 0.08%
1 day-0.01%
1 week+2.02%
Current month+2.02%
1 month+11.74%
3 months+43.86%
6 months+25.24%
Current year+24.91%
1 week 18,468
Extreme 18468
19,397
1 month 16,401
Extreme 16401
19,397
Current year 11,500
Extreme 11500
19,397
1 year 11,500
Extreme 11500
19,747
3 years 2,870.1
Extreme 2870.1
19,747
5 years 967
Extreme 967
19,747
10 years 245.75
Extreme 245.75
19,747
Manager TitleAgeSince
Chief Executive Officer 46 2026-03-31
Director of Finance/CFO - 2022-11-22
Chief Tech/Sci/R&D Officer - 2023-02-28
Director TitleAgeSince
Director/Board Member 50 2001-12-31
Chairman 82 1984-01-06
Director/Board Member 46 2007-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%+2.02% - - 2.54B
-1.14%-2.43%+53.72%+159.07% 1,070B
-1.41%+0.32%+66.23%+60.48% 624B
-2.42%+0.18%+34.59%+85.62% 450B
-1.20%+0.53%+31.00%+25.82% 328B
+0.57%+0.55%+38.76%+40.24% 292B
+0.29%-1.03%+28.35%+47.54% 284B
+2.19%+3.86%-25.94%-39.15% 217B
-2.06%+1.63%+22.87%+64.34% 198B
-1.26%+2.60%+15.98%+70.00% 161B
Average -0.63%+1.07%+29.51%+57.11% 402.71B
Weighted average by Cap. -0.94%+0.77%+40.12%+81.60%

Financials

2026 2027 *
Net sales 17.64B 185M 162M 149M 138M 263M 266M 1.79B 695M 8.66B 694M 679M 30.02B 23.33B 245M 214M 197M 183M 348M 352M 2.36B 919M 11.45B 918M 898M 39.7B
Net income 2.57B 26.97M 23.62M 21.76M 20.19M 38.35M 38.87M 260M 101M 1.26B 101M 99.06M 4.38B 4.21B 44.13M 38.65M 35.6M 33.04M 62.75M 63.59M 426M 166M 2.07B 166M 162M 7.16B
Net Debt -117M -1.22M -1.07M -985K -915K -1.74M -1.76M -11.79M -4.59M -57.19M -4.59M -4.49M -198M -3.18B -33.39M -29.24M -26.93M -25M -47.47M -48.11M -322M -125M -1.56B -125M -123M -5.42B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
1,794
Date Price Change Volume
26-07-07 18,955.00 -0.01% 48,620
26-07-06 ₹18,956.00 +0.06% 34,185
26-07-03 ₹18,944.00 -0.23% 75,135
26-07-02 ₹18,988.00 +1.08% 32,222
26-07-01 ₹18,786.00 +1.11% 43,004
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
18,858.95INR
Average target price
20,972.00INR
Spread / Average Target
+11.20%

Quarterly revenue - Rate of surprise